Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) presented an update on the company at the 26th Annual ROTH Conference at 12:30 p.m. PDT, March 11, 2014, at The Ritz-Carlton, Dana Point in California. Biota Pharmaceuticals Inc (NASDAQ:BOTA) stock performance was 10.15% in last session and finished the day at $6.62. Traded volume was 449,674 million shares in the last session and the average volume of the stock remained 157.70 million shares. The beta of the stock remained 1.17. Biota Pharmaceuticals Inc (NASDAQ:BOTA) insider ownership is 19.50%.

OncoGenex Pharmaceuticals (NASDAQ:OGXI) CEO Scott Daniel Cormack unloaded 4,634 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $12.25, for a total transaction of $56,766.50.OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) rose 5.42 percent to $13.22 yesterday on volume of 384,822.00 million shares. The intra-day range of the stock was $12.12 to $13.55. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) has a market capitalization of $194.58 million.

Vermillion, Inc. (NASDAQ:VRML) had an attractive trading day on Thursday in last week. The company witnessed its shares jumping 6.05 percent to $2.98 by bell time. That gain came on solid volume of shares too, where almost three times the normal volume was traded. Vermillion, Inc. (NASDAQ:VRML)’s stock on Mar 21, 2014 reported an increase of 10.07% to the closing price of $3.28. Its fifty two weeks range is $1.03 -$ 4.07. The total market capitalization recorded $117.51 billion. The overall volume in the last trading session was 23.48 million shares. In its share capital, Vermillion, Inc. (NASDAQ:VRML) has 2.00 million outstanding shares.

Genetic Technologies Limited (ASX: GTG) (NASDAQ:GENE) announced the recent online publication in the journal Applied Health Economics and Health Policy of a study entitled, “Economic Evaluation of Using a Genetic Test to Direct Breast Cancer Chemoprevention in White Women With a Previous Breast Biopsy. On Friday, shares of Genetic Technologies Limited (ADR) (NASDAQ:GENE) advanced 5.77% to close the day at $1.65. Company return on investment (ROI) is -164.70% and its monthly performance is recorded as -5.17%. Genetic Technologies Limited (ADR) (NASDAQ:GENE) quarterly revenue growth is 13.79%.